Horizon Pharma plc Announces Exceptional Third-Quarter 2015 Financial Results and Significantly Raises Full-Year 2015 Sales and Adjusted EBITDA Guidance; Net Sales of $226.5 Million, Up 202 Percent; Adjusted EBITDA of $131.1 Million; GAAP Net Income of $3.3 Million; Adjusted Operating Cash Flow of $100.8 Million; GAAP Operating Cash Flow of $88.4 Million; $684.3 Million of Cash; Net Debt/LTM Adjusted EBITDA Leverage Ratio of 2.1x; Raises Full-Year 2015 Net Sales Guidance to $750 to $760 Million; Raises Full-Year Adjusted EBITDA Guidance to $350 to $360 Million.
In: Marketwired, 2015-11-06
Zeitungsartikel
Zugriff:
| Titel: |
Horizon Pharma plc Announces Exceptional Third-Quarter 2015 Financial Results and Significantly Raises Full-Year 2015 Sales and Adjusted EBITDA Guidance; Net Sales of $226.5 Million, Up 202 Percent; Adjusted EBITDA of $131.1 Million; GAAP Net Income of $3.3 Million; Adjusted Operating Cash Flow of $100.8 Million; GAAP Operating Cash Flow of $88.4 Million; $684.3 Million of Cash; Net Debt/LTM Adjusted EBITDA Leverage Ratio of 2.1x; Raises Full-Year 2015 Net Sales Guidance to $750 to $760 Million; Raises Full-Year Adjusted EBITDA Guidance to $350 to $360 Million.
|
|---|---|
| Link: | |
| Zeitschrift: | Marketwired, 2015-11-06 |
| Veröffentlichung: | 2015 |
| Medientyp: | Zeitungsartikel |
| Sonstiges: |
|